Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2529) 2529
Publication (131) 131
Book Review (28) 28
Book / eBook (20) 20
Magazine Article (8) 8
Book Chapter (6) 6
Data Set (5) 5
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1625) 1625
male (1520) 1520
hyperlipidemias - chemically induced (1326) 1326
animals (1050) 1050
female (932) 932
hyperlipidemia (751) 751
hyperlipidemias - drug therapy (635) 635
index medicus (629) 629
rats (624) 624
adult (611) 611
middle aged (597) 597
triglycerides - blood (543) 543
cholesterol - blood (433) 433
hyperlipidemias - blood (351) 351
lipids - blood (350) 350
risk factors (343) 343
pharmacology & pharmacy (322) 322
cholesterol (303) 303
hiv infections - drug therapy (291) 291
aged (272) 272
mice (259) 259
hyperlipidemias - complications (248) 248
hyperlipidemias - metabolism (244) 244
liver - metabolism (222) 222
lipids (200) 200
hypolipidemic agents - therapeutic use (194) 194
atherosclerosis (186) 186
disease models, animal (183) 183
liver - drug effects (173) 173
metabolism (168) 168
lipid metabolism (163) 163
rats, wistar (162) 162
hiv protease inhibitors - adverse effects (160) 160
insulin-resistance (159) 159
lipoproteins - blood (158) 158
time factors (153) 153
immunology (151) 151
insulin resistance (150) 150
infectious diseases (146) 146
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (140) 140
hypolipidemic agents - pharmacology (140) 140
triglycerides (139) 139
rats, sprague-dawley (137) 137
protease inhibitors (134) 134
medicine, general & internal (132) 132
rabbits (131) 131
dose-response relationship, drug (129) 129
risk (129) 129
antiretroviral therapy, highly active - adverse effects (127) 127
oxidative stress (127) 127
therapy (127) 127
biochemistry & molecular biology (126) 126
drug therapy, combination (125) 125
hyperlipidemias - prevention & control (124) 124
adolescent (123) 123
hypercholesterolemia (122) 122
research (120) 120
cholesterol, ldl - blood (119) 119
liver (118) 118
antipsychotic agents - adverse effects (115) 115
diabetes (114) 114
cardiac & cardiovascular systems (113) 113
anti-hiv agents - adverse effects (111) 111
lipoproteins (111) 111
diet (110) 110
dyslipidemia (110) 110
hypolipidemic agents - adverse effects (110) 110
disease (109) 109
lipodystrophy (109) 109
obesity (109) 109
treatment outcome (109) 109
statins (107) 107
hyperlipidemias - etiology (106) 106
endocrinology & metabolism (105) 105
health aspects (103) 103
cholesterol, hdl - blood (101) 101
retrospective studies (101) 101
hiv (100) 100
hyperlipidemias - pathology (100) 100
rhabdomyolysis - chemically induced (98) 98
blood glucose - metabolism (97) 97
hyperlipidemias - epidemiology (97) 97
hypercholesterolemia - chemically induced (95) 95
drug interactions (94) 94
hypertriglyceridemia - chemically induced (92) 92
drug therapy (91) 91
hiv infections - complications (91) 91
diabetes mellitus - chemically induced (90) 90
fatty acids, nonesterified - blood (90) 90
hyperlipidemias - genetics (90) 90
hypertriglyceridemia (90) 90
peripheral vascular disease (90) 90
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (89) 89
plant extracts - pharmacology (88) 88
psychiatry (88) 88
glucose (87) 87
physiological aspects (87) 87
analysis (86) 86
hypertension (86) 86
care and treatment (85) 85
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2229) 2229
French (88) 88
German (78) 78
Spanish (35) 35
Russian (34) 34
Japanese (23) 23
Polish (22) 22
Italian (15) 15
Chinese (10) 10
Hebrew (5) 5
Dutch (4) 4
Romanian (4) 4
Swedish (4) 4
Norwegian (3) 3
Bulgarian (2) 2
Finnish (2) 2
Ukrainian (2) 2
Croatian (1) 1
Danish (1) 1
Hungarian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Understanding, recognizing, and managing toxicities of targeted anticancer therapies
by Dy, Grace K and Adjei, Alex A
CA: A Cancer Journal for Clinicians, ISSN 0007-9235, 07/2013, Volume 63, Issue 4, pp. 249 - 279
Answer questions and earn CME/CNE Advances in genomics and molecular biology have identified aberrant proteins in cancer cells that are attractive targets for... 
toxicity | kinase inhibitors | therapeutic index | targeted agents | mechanism‐based toxicity | immunotherapeutic agents | off‐target toxicity | mechanism-based toxicity | off-target toxicity | MEK INHIBITOR TRAMETINIB | PULMONARY ARTERIAL-HYPERTENSION | I DOSE-ESCALATION | CHRONIC MYELOID-LEUKEMIA | GROWTH-FACTOR RECEPTOR | ONCOLOGY | PLACEBO-CONTROLLED TRIAL | III CLINICAL-TRIAL | SQUAMOUS-CELL CARCINOMAS | TIVANTINIB ARQ 197 | SIGNAL-REGULATED KINASE | Mood Disorders - chemically induced | Drug Eruptions - etiology | Peripheral Nervous System Diseases - chemically induced | Bone Marrow Diseases - chemically induced | Cachexia - chemically induced | Endocrine System Diseases - chemically induced | Pleural Effusion - chemically induced | Humans | Drug Eruptions - therapy | Immune System Diseases - chemically induced | Lung Diseases, Interstitial - chemically induced | Thrombocytopenia - chemically induced | Diarrhea - chemically induced | Neoplasms - drug therapy | Antineoplastic Agents - adverse effects | Exanthema - chemically induced | Hyperbilirubinemia - chemically induced | Venous Thromboembolism - chemically induced | Vision Disorders - chemically induced | Hemorrhage - chemically induced | Heart Diseases - chemically induced | Hyperlipidemias - chemically induced | Magnesium - blood | Antimitotic agents | Drugs | Prevention | Complications and side effects | Drug targeting | Antineoplastic agents | Health aspects | Risk factors | Proteins | Side effects | Genomics | Cytotoxicity | Molecular biology | Cancer therapies | Cells | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Lipidomics Identification of Metabolic Biomarkers in Chemically Induced Hypertriglyceridemic Mice
by Kwan, Hiu Yee and Hu, Yong-Mei and Chan, Chi Leung and Cao, Hui-Hui and Cheng, Chi Yan and Pan, Si-Yuan and Tse, Kai Wing and Wu, Yiu Cheong and Yu, Zhi-Ling and Fong, Wang Fun
Journal of Proteome Research, ISSN 1535-3893, 03/2013, Volume 12, Issue 3, pp. 1387 - 1398
In this study, we aim to identify the potential biomarkers in hTG pathogenesis in schisandrin B-induced hTG mouse model. To investigate whether these... 
malonyl CoA | quantification | high-resolution MS/MS fragmentation | reversed phase liquid chromatography (RPLC) | MALONYL-COENZYME-A | OXIDATION | FATTY LIVER-DISEASE | HYPERLIPIDEMIA | BIOCHEMICAL RESEARCH METHODS | MUSCLE | OBESITY | INHIBITION | DIET | DENSITY-LIPOPROTEIN | SCHISANDRIN-B | Biomarkers - metabolism | Reproducibility of Results | Hypertriglyceridemia - metabolism | Lipids | Calibration | Lignans - pharmacology | Polycyclic Compounds - pharmacology | Tandem Mass Spectrometry | Hypertriglyceridemia - chemically induced | Animals | Triglycerides - blood | Chromatography, Liquid | Cyclooctanes - pharmacology | Mice | Principal Component Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Statin-Associated Side Effects
by Thompson, Paul D., MD and Panza, Gregory, MS and Zaleski, Amanda, MS and Taylor, Beth, PhD
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2016, Volume 67, Issue 20, pp. 2395 - 2410
Abstract Hydroxy-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors or statins are well tolerated, but associated with various statin-associated... 
Cardiovascular | Internal Medicine | rhabdomyolysis | skeletal muscle | interstitial lung disease | myopathy | C-REACTIVE PROTEIN | RANDOMIZED CONTROLLED-TRIALS | CARDIAC & CARDIOVASCULAR SYSTEMS | FORCE 2014 UPDATE | PRIMARY-PREVENTION TRIAL | INDUCED MUSCLE TOXICITY | INTERSTITIAL LUNG-DISEASE | CENTRAL-NERVOUS-SYSTEM | OF-THE-LITERATURE | CORONARY-HEART-DISEASE | TYPE-2 DIABETES-MELLITUS | Liver Function Tests | Sleep Wake Disorders - chemically induced | Hydroxymethylglutaryl-CoA Reductase Inhibitors - immunology | Myalgia - chemically induced | Humans | Hyperlipidemias - drug therapy | Risk Factors | Lung Diseases, Interstitial - chemically induced | Tendon Injuries - chemically induced | Necrosis - chemically induced | Brain - drug effects | Rupture - chemically induced | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Stroke - chemically induced | Cognition Disorders - etiology | Depression - chemically induced | Rhabdomyolysis - chemically induced | Antibodies - blood | Diabetes Mellitus - chemically induced | Acute Kidney Injury - chemically induced | Muscular Diseases - chemically induced | Testosterone - blood | Autoimmune Diseases - chemically induced | Hyperlipidemias - complications | Viral antibodies | Complications and side effects | Enzymes | Thiols | Antibodies | Diabetes | Cardiology | Statins | Cardiovascular agents | Creatine kinase | Muscles | Creatine | Respiratory tract diseases | Studies | Musculoskeletal system | Genotype & phenotype | Mortality | Clinical trials | Lipids | Clinical medicine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Physical Health Monitoring of Patients With Schizophrenia
by Marder, Stephen R and Essock, Susan M and Miller, Alexander L and Buchanan, Robert W and Casey, Daniel E and Davis, John M and Kane, John M and Lieberman, Jeffrey A and Schooler, Nina R and Covell, Nancy and Stroup, Scott and Weissman, Ellen M and Wirshing, Donna A and Hall, Catherine S and Pogach, Leonard and Pi-Sunyer, Xavier and Bigger, J. Thomas and Friedman, Alan and Kleinberg, David and Yevich, Steven J and Davis, Bonnie and Shon, Steven
American Journal of Psychiatry, ISSN 0002-953X, 08/2004, Volume 161, Issue 8, pp. 1334 - 1349
OBJECTIVE: Schizophrenia is associated with several chronic physical illnesses and a shorter life expectancy, compared with life expectancy in the general... 
DIABETES-MELLITUS | PSYCHIATRY | ANTIPSYCHOTIC-DRUGS | BODY-MASS INDEX | PROLACTIN LEVELS | RISPERIDONE | INDUCED WEIGHT-GAIN | OLANZAPINE | CORONARY-HEART-DISEASE | CLOZAPINE USE | SERUM TRIGLYCERIDE LEVELS | Clozapine - therapeutic use | Myocarditis - chemically induced | Cataract - chemically induced | Antipsychotic Agents - adverse effects | Humans | Long QT Syndrome - chemically induced | Sexual Dysfunctions, Psychological - chemically induced | Myocarditis - diagnosis | Hyperlipidemias - diagnosis | Sexual Dysfunctions, Psychological - diagnosis | Long QT Syndrome - diagnosis | Schizophrenia - diagnosis | Antipsychotic Agents - therapeutic use | Hyperprolactinemia - diagnosis | Basal Ganglia Diseases - diagnosis | Adult | Obesity - diagnosis | Weight Gain | Basal Ganglia Diseases - chemically induced | Cataract - diagnosis | Hyperprolactinemia - chemically induced | Diabetes Mellitus, Type 2 - diagnosis | Monitoring, Physiologic - methods | Diabetes Mellitus, Type 2 - chemically induced | Schizophrenia - drug therapy | Clozapine - adverse effects | Health Status | Hyperlipidemias - chemically induced | Practice Guidelines as Topic | Schizophrenia | Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text The peroxisome proliferator-activated receptor (PPAR) α agonist fenofibrate suppresses chemically induced lung alveolar proliferative lesions in male obese hyperlipidemic mice
by Kuno, Toshiya and Hata, Kazuya and Takamatsu, Manabu and Hara, Akira and Hirose, Yoshinobu and Takahashi, Satoru and Imaida, Katsumi and Tanaka, Takuji
International Journal of Molecular Sciences, ISSN 1661-6596, 05/2014, Volume 15, Issue 5, pp. 9160 - 9172
Activation of peroxisome proliferator-activated receptor (PPAR) a disrupts growth-related activities in a variety of human cancers. This study was designed to... 
Hyperinsulinemia | 4-Nitroquinoline-1-oxide | Hyperlipidemia | Carcinogenesis | Chemoprevention | Lung neoplasms | hyperlipidemia | lung neoplasms | hyperinsulinemia | MODEL | CHEMISTRY, MULTIDISCIPLINARY | GROWTH-FACTOR AXIS | INSULIN | 4-nitroquinoline-1-oxide | chemoprevention | INHIBITION | carcinogenesis | CANCER-RISK | DYSLIPIDEMIA | POSTMENOPAUSAL WOMEN | TYPE-2 DIABETES-MELLITUS | CELL | TUMORIGENESIS | Receptor, IGF Type 1 - metabolism | Lung Neoplasms - metabolism | Lung Neoplasms - pathology | Male | Insulin - blood | Fenofibrate - therapeutic use | Fenofibrate - pharmacology | Pulmonary Alveoli - metabolism | Pulmonary Alveoli - drug effects | Phosphorylation - drug effects | Proto-Oncogene Proteins c-akt - metabolism | Pulmonary Alveoli - pathology | Hyperlipidemias - metabolism | Hyperlipidemias - drug therapy | Hypolipidemic Agents - pharmacology | Animals | Mitogen-Activated Protein Kinase 3 - metabolism | Hyperlipidemias - pathology | Mice, Obese | PPAR alpha - agonists | Cell Proliferation - drug effects | Hypolipidemic Agents - therapeutic use | Mice | PPAR alpha - metabolism | Insulin-Like Growth Factor I - metabolism | Mitogen-Activated Protein Kinase 1 - metabolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Adverse drug events associated with the use of analgesics, sedatives, and antipsychotics in the intensive care unit
by Devlin, John W and Mallow-Corbett, Stephanie and Riker, Richard R
Critical Care Medicine, ISSN 0090-3493, 06/2010, Volume 38 Suppl, Identification and Prevention of Common Adverse Drug Events in the Intensive Care Unit, Issue 6, pp. S231 - S243
As critically ill patients frequently receive analgesics, sedatives, and antipsychotics to optimize patient comfort and facilitate mechanical ventilation,... 
Coma | Delirium | Dverse drug events | Benzodiazepine | Critical care | Fentanyl | Opioid | Pharmacology | Haloperidol | Drug safety | Intensive care unit | Prevention | Analgesic | Dexmedetomidine | Antipsychotic | Lorazepam | Midazolam | Propofol | Sedative | dexmedetomidine | analgesic | propofol | critical care | QTC INTERVAL | MECHANICALLY VENTILATED PATIENTS | haloperidol | PROPOFOL INFUSION SYNDROME | midazolam | fentanyl | pharmacology | antipsychotic | intensive care unit | LONG-TERM SEDATION | sedative | delirium | prevention | benzodiazepine | CRITICAL CARE MEDICINE | drug safety | opioid | lorazepam | coma | ATYPICAL ANTIPSYCHOTICS | HIGH-DOSE DEXMEDETOMIDINE | adverse drug events | HUMAN NEUTROPHIL FUNCTIONS | TORSADE-DE-POINTES | PROPYLENE-GLYCOL TOXICITY | CRITICALLY-ILL PATIENTS | Critical Care - methods | Drug-Related Side Effects and Adverse Reactions - prevention & control | Hypnotics and Sedatives - adverse effects | Drug-Related Side Effects and Adverse Reactions - chemically induced | Endocrine System Diseases - chemically induced | United States | Antipsychotic Agents - adverse effects | Humans | Excipients - adverse effects | Fatty Liver - chemically induced | Infection - etiology | Muscular Diseases - chemically induced | Propofol - administration & dosage | Analgesics - adverse effects | Intensive Care Units | Infection - immunology | Acidosis - chemically induced | Substance Withdrawal Syndrome | Syndrome | Bradycardia - chemically induced | Immune System - drug effects | Nervous System Diseases - chemically induced | Cardiovascular Diseases - chemically induced | Infusions, Intravenous | Hyperlipidemias - chemically induced | Drug-Related Side Effects and Adverse Reactions - physiopathology | Gastrointestinal Diseases - chemically induced | Propofol - adverse effects | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Adverse effects of second-generation antipsychotics in children and adolescents: A bayesian meta-analysis
by Cohen, David and Bonnot, Olivier and Bodeau, Nicolas and Consoli, Angèle and Laurent, Claudine
Journal of Clinical Psychopharmacology, ISSN 0271-0749, 06/2012, Volume 32, Issue 3, pp. 309 - 316
In adults, second-generation antipsychotics (SGAs) have a low frequency of extrapyramidal syndrome (EPS) and a moderate frequency of metabolic adverse effects.... 
adolescence | adverse effects | meta-analysis | second-generation antipsychotics | childhood | CLOZAPINE | PLACEBO | PSYCHIATRY | OPEN-LABEL | RISPERIDONE | BIPOLAR DISORDER | EARLY-ONSET SCHIZOPHRENIA | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | WEIGHT-GAIN | OLANZAPINE | ARIPIPRAZOLE | Disorders of Excessive Somnolence - chemically induced | Hyperglycemia - chemically induced | Antipsychotic Agents - adverse effects | Humans | Adolescent | Bayes Theorem | Weight Gain - drug effects | Hyperprolactinemia - chemically induced | Hyperlipidemias - chemically induced | Child | Adolescence
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Antipsychotic-induced weight gain and metabolic abnormalities: Implications for increased mortality in patients with schizophrenia
by Casey, Daniel E and Haupt, Dan W and Newcomer, John W and Henderson, David C and Sernyak, Michael J and Davidson, Michael and Lindenmayer, Jean-Pierre and Manoukian, Steven V and Banerji, Mary Ann and Lebovitz, Harold E and Hennekens, Charles H
Journal of Clinical Psychiatry, ISSN 0160-6689, 2004, Volume 65, Issue 7, pp. 4 - 18
Patients with schizophrenia have increased rates of morbidity and mortality due primarily to cardiovascular disease, compared with the general population. Case... 
C-REACTIVE PROTEIN | DIABETES-MELLITUS | EXCESS MORTALITY | RISK-FACTORS | NUTRITION EXAMINATION SURVEY | PSYCHIATRY | 3RD NATIONAL-HEALTH | CARDIOVASCULAR-DISEASE | BODY-MASS INDEX | CORONARY-HEART-DISEASE | PSYCHOLOGY, CLINICAL | HIGH-DENSITY-LIPOPROTEIN | Myocardial Infarction - chemically induced | Myocardial Infarction - epidemiology | Myocardial Infarction - mortality | Prevalence | Antipsychotic Agents - adverse effects | Humans | Male | Metabolic Syndrome - chemically induced | Diabetic Ketoacidosis - mortality | Cause of Death | Hyperlipidemias - epidemiology | Antipsychotic Agents - therapeutic use | Schizophrenia - mortality | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Adult | Female | Weight Gain - drug effects | Diabetic Ketoacidosis - epidemiology | Obesity - mortality | Metabolic Syndrome - epidemiology | Obesity - chemically induced | Risk Factors | Insulin Resistance | Hyperlipidemias - mortality | Metabolic Syndrome - mortality | Obesity - epidemiology | Cardiovascular Diseases - chemically induced | Schizophrenia - drug therapy | Drug Monitoring | Hyperlipidemias - chemically induced | Diabetic Ketoacidosis - chemically induced
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Diet-Induced Obese Mice Retain Endogenous Leptin Action
by Ottaway, Nickki and Mahbod, Parinaz and Rivero, Belen and Norman, Lee Ann and Gertler, Arieh and D’Alessio, David A and Perez-Tilve, Diego
Cell Metabolism, ISSN 1550-4131, 06/2015, Volume 21, Issue 6, pp. 877 - 882
Obesity is characterized by hyperleptinemia and decreased response to exogenous leptin. This has been widely attributed to the development of leptin... 
SKELETAL-MUSCLE | RESPONSIVENESS | ANTAGONIST | DISRUPTION | METABOLISM | PHOSPHORYLATION | ENDOCRINOLOGY & METABOLISM | GENE-EXPRESSION | RESISTANCE | NEURONS | HYPOTHALAMUS | CELL BIOLOGY | Receptors, Leptin - antagonists & inhibitors | Hyperlipidemias - genetics | Obesity - chemically induced | Hyperlipidemias - metabolism | Receptors, Leptin - genetics | Diet - adverse effects | Leptin - metabolism | Suppressor of Cytokine Signaling Proteins - genetics | Receptor, Melanocortin, Type 4 - metabolism | Leptin - genetics | Receptor, Melanocortin, Type 4 - genetics | Body Weight - genetics | Obesity - genetics | Mice, Knockout | Obesity - metabolism | Suppressor of Cytokine Signaling 3 Protein | Animals | Mice, Obese | Mice | Receptors, Leptin - metabolism | Suppressor of Cytokine Signaling Proteins - metabolism | Hyperlipidemias - chemically induced | Jewish schools | Obesity | Leptin | Analysis | Body weight
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights